Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of vorinostat and bortezomib in the
third line treatment of advanced NSCLC, as well as to assess toxicity (including neuropathy)
and tolerability of this regimen.
Phase:
Phase 2
Details
Lead Sponsor:
University of Wisconsin, Madison
Collaborators:
Merck Sharp & Dohme Corp. Millennium Pharmaceuticals, Inc.